Ojurongbe Olusola, Ogungbamigbe Titus O, Fagbenro-Beyioku Adetayo F, Fendel Rolf, Kremsner Peter G, Kun Jürgen F J
Department of Parasitology, Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Malar J. 2007 Apr 11;6:41. doi: 10.1186/1475-2875-6-41.
Chloroquine (CQ) has been in use in Africa for a long time. Because of misuse, this drug has now lost its efficacy due to the emergence of resistance strains in most parts of Africa. Recently, it was shown that after chloroquine has been withdrawn from the market, chloroquine-sensitive Plasmodium falciparum re-emerged and chloroquine could again be used successfully as an antimalarial. Surveillance of parasite populations is, therefore, important to decide whether chloroquine could be re-introduced.
To estimate the prevalence of the most pivotal polymorphisms, including Pfcrt K76T, Pfmdr1 N86Y and Pfmdr1 Y184F mutations, and their contributions to the outcome of CQ treatment, isolates from Osogbo Western Nigeria were tested using the Fluorescence Resonance Energy Transfer (FRET) method on a real-time PCR instrument.
116 children with acute uncomplicated P. falciparum malaria infections were treated with the standard dosage of CQ and followed-up for 28 days. Blood samples were collected on filter paper at enrollment and during follow-up for identification of parasite carrying the chloroquine resistant transporter (pfcrt) and P. falciparum-multi drug resistance (pfmdr1) gene mutations. Parasitological assessment of response to treatment showed that 62% of the patients were cured and 38% failed the CQ treatment. The presence of single mutant pfcrt (T76) alleles (P = 0.003) and in combination with mutant pfmdr1 Y86 (P = 0.028) was significantly associated with in vivo CQR. No other mutation on its own or in combinations was significantly associated with treatment outcome. Mutant pfcrt was more prevalent in both pre- and post-treatment isolates. No association was observed between age or initial level of parasitaemia and chloroquine treatment outcome.
The result established the usefulness and accuracy of real time PCR in pfcrt and pfmdr1 mutation detection and also give further evidence to the reliability of the pfcrt T76 point mutation as a molecular marker for CQ resistance.
氯喹(CQ)在非洲已使用很长时间。由于滥用,这种药物如今在非洲大部分地区因耐药菌株的出现而失去了疗效。最近有研究表明,在氯喹退出市场后,对氯喹敏感的恶性疟原虫再度出现,氯喹能够再次成功用作抗疟药物。因此,监测寄生虫种群对于决定是否可重新引入氯喹很重要。
为估计包括Pfcrt K76T、Pfmdr1 N86Y和Pfmdr1 Y184F突变在内的最关键多态性的流行情况及其对氯喹治疗结果的影响,在实时PCR仪器上使用荧光共振能量转移(FRET)方法对来自尼日利亚西部奥索博的分离株进行检测。
116名急性非复杂性恶性疟原虫疟疾感染儿童接受了标准剂量的氯喹治疗,并随访28天。在入组时和随访期间采集滤纸血样,以鉴定携带氯喹抗性转运蛋白(pfcrt)和恶性疟原虫多药耐药(pfmdr1)基因突变的寄生虫。对治疗反应的寄生虫学评估显示,62%的患者治愈,38%的患者氯喹治疗失败。单一突变pfcrt(T76)等位基因的存在(P = 0.003)以及与突变pfmdr1 Y86联合存在(P = 0.028)与体内氯喹抗性显著相关。其他任何单独或联合的突变与治疗结果均无显著关联。突变pfcrt在治疗前和治疗后的分离株中更为普遍。未观察到年龄或初始寄生虫血症水平与氯喹治疗结果之间存在关联。
该结果证实了实时PCR在检测pfcrt和pfmdr1突变方面的实用性和准确性,也进一步证明了pfcrt T76点突变作为氯喹抗性分子标志物的可靠性。